Nutraceuticals as therapeutic interventions in Alzheimer's disease

Abstract

Alzheimer's disease (AD) is a chronic neurodegenerative disease of the brain. Currently, approximately 55 million people have dementia across the globe and the number of AD patients is estimated by the WHO to reach about 78 million people by 2030 and nearly 139 million by 2050 globally. Amyloid β42, amyloid β oligomers, and tau proteins are the major biomarkers to understand the AD-like pathology. Therapies target β-amyloid (Aβ) for the modification of AD but poor permeability hampers the uses of drugs against AD. Other drugs including NMDA-receptor antagonists, cholinesterase inhibitors and their combination provide only temporary symptomatic relief. Meanwhile nutraceuticals are studied for mitigating the course of dementia. This study reviews therapeutic nutraceuticals which could be effective for treating AD.